ARW ON RNA
Scaling Personalization: Inside The Manufacturing & Analytical Hurdles Of mRNA Cancer Immunotherapies
As we know from the autologous cell therapies that have come before us, manufacturing and scaling personalized products is no mean feat, and there are a handful of efforts we need to be tackling today to realize a more efficient and (ideally) decentralized manufacturing process. Fortunately for us, the panel had a few ideas on what it will take to make our analytical development and manufacturing more efficient processes.
OUR EXPERT NETWORK
-
Unlocking Established Immunological Pathways: How mRNA And LNP Technologies Can Reshape Cancer Therapy
The latest generation of LNP technologies holds the promise of delivering therapies to precise cells and tissues outside the liver, while mRNA technology allows transient protein expression to be maintained.
-
The Hidden Biology Of RNA Impurities: When Manufacturing Changes Therapeutic Behavior
Two mRNA batches may contain the same intended therapeutic sequence yet produce different biological responses. One explanation lies in the unintended RNA species generated during manufacturing.
-
Comparing Advanced Modality Needs, Part 1: Manufacturing
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
-
4 Delivery Science Lessons For RNA Developers
Drawing on published science, current guidance, and the author's own perspective, four delivery science lessons become clear for RNA developers.
-
Two Parallel Trials, A Potential New Option For Protection From COVID-19
Invivyd’s Michael Mina, MD, Ph.D., discusses LIBERTY and DECLARATION, exploring how monoclonal antibodies could expand COVID-19 protection alongside vaccines.
WEBINARS
MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
RNA HOT TAKES
- Sticks, Carrots, & Carolina Reapers: Fact-Checking The "Death" Of The US mRNA Industry
- mRNA Hot Takes: Ghost Peppers & Global R&D
- mRNA Hot Takes: Habaneros & Headwinds
- The Trough Of Disillusionment: 2026 RNA Reality Checks
- mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026
- mRNA Hot Takes: Building A Solid Foundation For Your RNA Company & Products
EDITORIAL COLLECTIONS
Complex questions in RNA rarely have simple answers. Our Editorial Collections gather essential perspectives in one place, giving you a closer look at the decisions, technologies, and challenges influencing the field.
More Editorial CollectionsVIRTUAL EVENTS
- Nobody Puts Plasmid In A Corner: Essential Considerations For mRNA Production
- The mRNA Therapeutics Regulatory Paradigm: A Closer Look
- Evolutions in mRNA Drug Product Analytical Development
- Closing The Adoption Gap For Advanced Single-Use Materials
- Advancements in gRNA Manufacturing & Quality
- Chemoenzymatic Ligation: A New Frontier In siRNA Manufacturing
NEWSLETTER ARCHIVE
- 11.19.26 -- What If The Body Could Make Its Own Medicine?
- 11.18.26 -- Which mRNA-LNP CQAs Deserve More Attention Today?
- 11.11.26 -- Confronting The Operational Burden Of mRNA Release
- 11.11.26 -- Simplify The Journey Of Advancing Your Therapies To Patients
- 11.07.26 -- Advancing RNA Newsletter Best Of October
- 11.04.26 -- The In Vivo CAR-T Boom: Where Does mRNA Fit In?
